이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

LIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1) (LPP1)

2026년 11월 12일 업데이트: Institut Pasteur de Lille

Effect of the Dietary Supplement LIPI-PROTECT-1 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.

This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-1.

The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.

A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.

The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.

LIPI-PROTECT-1 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.

This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-1 in adults with untreated moderate hypercholesterolemia.

A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-1 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.

The primary objective is to assess the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.

Secondary objectives are to evaluate the effect of LIPI-PROTECT-1 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).

Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.

Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.

연구 유형

중재적

등록 (실제)

20

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Nord
      • Lille, Nord, 프랑스, 59019
        • Prevention research center - Institut Pasteur de Lille
    • Vaucluse
      • Avignon, Vaucluse, 프랑스, 84140
        • Biophysium

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

- Men and women aged 18-65 years

For women :

If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the study If post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)

  • LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
  • Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
  • BMI between 20 and 35 kg/m² (inclusive)
  • Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
  • Willing to comply with study requirements
  • Signed informed consent

Exclusion Criteria:

  • Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
  • Subjects with triglyceride levels > 4 g/L
  • Subjects requiring immediate lipid-lowering therapy
  • Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
  • Subjects receiving beta-blockers and/or diuretics
  • Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
  • Subjects receiving anticoagulant therapy
  • Subjects receiving antiretroviral therapy
  • Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
  • Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function) Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
  • Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
  • Subjects with an allergy to any of the components of LIPI-PROTECT-1
  • Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months
  • Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
  • Subjects participating in another clinical study or currently within the exclusion period of another study
  • Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Food supplement group

Three tablets of LIPI-PROTECT-1 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers

All subjects will consume 3 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 tablets in the evening during dinner. If a dose is missed, 1 tablet can be taken at the next dose

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
기간: To baseline at 3 months

To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months

2차 결과 측정

결과 측정
측정값 설명
기간
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
기간: To baseline at 3 months

To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-1 on LDL cholesterol.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Non HDL cholesterol.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on total cholesterol.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on HDL cholesterol.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on triglycerides.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on non HDL cholesterol/LDL (atherogenic index).
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio LDL/HDL.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio total cholesterol/HDL.
기간: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on fasting blood glucose levels.
기간: At baseline, 1 month and 3 months

Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on weight.
기간: At baseline, 1 month and 3 months

Changes in weight (unit : kilograms) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Body Mass Index (BMI).
기간: At baseline, 1 month and 3 months

Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on waist circumference.
기간: At baseline, 1 month and 3 months

Changes in waist circumference (unit: cm) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on arterial blood pressure
기간: At baseline, 1 month and 3 months

Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on heart rate
기간: At baseline, 1 month and 3 months

Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism: ASAT/ALAT, GGT
기간: At baseline, 1 month and 3 months

Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism : Creatinine, bilirubin
기간: At baseline and 3 months

Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Urea
기간: At baseline and 3 months

Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Creatinine Phophoskinase (CPK)
기간: At baseline and 3 months

Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on Renal metabolism : Lactate Deshydrogenase (LDH)
기간: At baseline and 3 months

Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.

At baseline and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by pillbox weighing
기간: At baseline, 1 month and 3 months

Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).

At baseline, 1 month and 3 months
To assess self-reported adherence to LIPI-PROTECT-1 consumption
기간: At 1 month, 2 months and 3 months

Adherence assessed through participant self-reporting of supplement consumption and missed doses.

At 1 month, 2 months and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by counting returned tablets
기간: At 3 months

Adherence assessed by counting the remaining tablets returned by participants at the end of the study.

At 3 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Coralie Berthier, PhD, Institut Pasteur de Lille

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 18일

기본 완료 (추정된)

2027년 1월 31일

연구 완료 (추정된)

2027년 3월 30일

연구 등록 날짜

최초 제출

2026년 11월 3일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2026-A00450-51

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .